Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Merck’s cladribine data to be presented by Dr Giovannoni

Merck’s cladribine data to be presented by Dr Giovannoni

31st March 2009

Merck’s latest data of its cladribine tablets investigation will be presented by Dr Gavin Giovannoni from the London School of Medicine and Dentistry.

As the study’s lead principal investigator, he will make a speech at the American Academy of Nerology’s 61st annual meeting on April 29th.

The body accepted the late-breaking abstract regarding the drug as an oral investigational treatment for multiple sclerosis.

Data from the trials will not be released until the meeting.

The report which Dr Giovannoni will discuss is titled: “Results from the Clarity-a study: a Phase III, randomized, double-blind study to evaluate the safety and efficacy of oral cladribine in relapsing-remitting multiple sclerosis.”

Earlier this month, Merck announced the formation of Serono Ventures ? a strategic, corporate venture capital fund to invest in emerging biotechnology companies.

Bernhard Kirschbaum, executive vice-president of research and development at Merck Serono, explained start-up companies are a vital element in scientific innovation.

He commented: “The creation of a venture capital fund underlines our commitment to be best partner for biotech entrepreneurs and their investors.”

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.